CSI Market
Sign In | Register

Enveric Biosciences Inc (ENVB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ENVB Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Enveric Biosciences Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-4.66
Depreciation & amortization0.07
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.21
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Premiums Receivable Allowance For Doubtful Accounts Recoveries-
Interest And Debt Expense-
Dividends Preferred Stock-
Change In Estimate Of Contingent Consideration-
Stock Option Restricted Stock Unit And Warrant Expense-
Accrued Interest-
Inducement Expense-
Operating Lease Right Of Use Asset Amortization Expense-
Impairment Of Intangible Assets And Goodwill-
Noncash Income Tax Expense-
Derivative Gain Loss On Derivative Net-
Write Off Of Deferred Offering Costs0.02
Income taxes0.00
Gain (Loss) on Investments0.00
Accounts Receivable0.00
Accounts Payable-0.07
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.28
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.53
Discontinued operations0.00
Net Cash flow from Operating Activities-4.70
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Amalgamation Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.81
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock5.55
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.02
Loans From Stockholders-
Loans From Shareholders-
Loans From Officers-
Loans From Stockholders-
Stock Redeemed Or Called During Period Value-
Adjustments To Additional Paid In Capital Warrant Issued-
Contingent Consideration For Acquisitions-
Proceeds From Offering And Reverse Merger Proceeds-
Proceeds From Issuance Of Private Placement One-
Proceeds From Warrant Exercise-
Proceeds From Common Stock Sold Under Purchase Agreement Net Of Offering Costs-
Payment For Equity Distribution Offering Costs-
Proceeds From Common Stock Sold For Cash Pursuant To Atm Agreement Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities8.35
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.70
Total Cash Flow3.62
4 historic quarters locked

Sign in to unlock the full Enveric Biosciences Inc cash flow history.

Sign In Create Free Account

About Enveric Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038418

Figures are derived from filed reports and may be restated. Historical data is subject to revision.